Accès ouvert
2026
article
OpenAlex
Savaş Gökçek, Pervin Can Sanci, Anıl Karakayalı, Emine Bihter Eniseler et autres
Background and Objectives: This study aimed to evaluate the effects of 24 h versus 46 h continuous 5-fluorouracil (5-FU) infusion durations on pathological response, progression-free survival (PFS), and overall survival (OS) in patients with gastric and gastroesophageal junction adenocarcinoma receiving a perioperative …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Halil Göksel Güzel, D. Kivrak Salim, Saadettin Kılıçkap, Yasemi̇n Kemal et autres
AIM: IMpower133 was designed with 4 cycles of chemoimmunotherapy with atezolizumab, unlike many other studies permitted 6-cycle induction. This study aimed to compare the efficacy and safety of a 4-cycle regimen with an extended 6-cycle regimen of carboplatin, etoposide, and atezolizumab in …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Halil Göksel Güzel, Derya Kıvrak Salim, Ece Ulukal Karancı, Mehmet Acun et autres
Purpose: The prognostic value of cetuximab-related electrolyte disturbances in metastatic colorectal cancer (CRC) remains unclear. The available reports on the prognostic effect of hypomagnesemia are controversial, while there are no comprehensive analyses regarding hypokalemia. This study aimed to evaluate the impact of …
tr
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Ömer Faruk Kuzu, Nuri Karadurmuş, Nebi Batuhan Kanat, Çağlar Köseoğlu et autres
Background: The role of high-dose chemotherapy followed by autologous stem-cell transplantation (HDCT–ASCT) in advanced Ewing sarcoma remains uncertain, with mixed prospective data and heterogeneous retrospective findings. Materials and Methods: We performed a single-center, retrospective cohort study of consecutive patients with histologically confirmed …
tr, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Ömer Faruk Kuzu, Nuri Karadurmuş, Nebi Batuhan Kanat, Çağlar Köseoğlu et autres
Background and Objectives: Relapsed or refractory germ cell tumors are commonly treated with HDCT/ASCT, but robust predictors of hematopoietic recovery are limited. Quantitative CT-based metrics of body composition are readily available, but their prognostic value for post-transplant engraftment remains uncertain. We investigated …
tr, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Alper Topal, Goncagül Akdağ, Aysegul Dumludag, Çağlar Köseoğlu et autres
disease will progress to the metastatic stage.[2][3][4] In metastatic patients, 5-year survival is less than 20%.5 For metastatic disease, the backbone of treatment is 5-fluorouracil (5-FU)-based regimens.These include 5-FU+irinotecan (FOLFIRI), capecitabine+oxaliplatin, and 5-FU+oxaliplatin (FOLFOX).6 In selected patients, triplet ABSTRACT Objective: Colorectal cancer …
kh, tr, ag
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Ömer Faruk Kuzu, Nuri Karadurmuş, Nebi Batuhan Kanat, Çağlar Köseoğlu et autres
Background Relapsed or refractory Germ cell tumors are commonly treated with HDCT/ASCT, yet robust predictors of hematopoietic recovery are limited. Quantitative CT-based body-composition metrics are readily available in practice, but their prognostic value for post-transplant engraftment remains uncertain. We investigated whether muscle …
tr, gb, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Gül Sema Yıldıran Keskin, İsmail ERTÜRK, Musa Barış AYKAN, Ramazan Acar et autres
Gastric cancer is one of the most common types of cancer.However, despite a significant decrease in the incidence of this cancer over the past two decades, it remains a leading cause of cancer-related deaths worldwide. 1Improved treatment strategies are, therefore, necessary as …
tr
(code pays fourni par la source)
2023
article
OpenAlex
Zeynep Tuğba Özdemir, Ezgi Çevik, Berna Çakmak Öksüzoğlu, Mutlu Doğan et autres
tr, kh, ag
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Musa Barış Aykan, Gül Sema Yıldıran Keskin, Ece Örnek, Alper Topal et autres
Background: Pazopanib acts as a multitargeted tyrosine kinase inhibitor.It has been shown to be effective in patients with advanced stage Soft Tissue Sarcomas (STSs).We aimed to evaluate survival times and significant side effects by making a retrospective evaluation of real-life data. Materials …
kh, Somalie
(code pays fourni par la source)